In vitro antitumor activity of MIC2 protein-doxorubicin conjugates

International Journal of Oncology

Volumn 9, Issue 3, 1996, Pages 527-531

  Gabor, Franz ^a   Haberl, Ines ^a   Wirth, Michael ^a   Richter, Klaus ^b   Theyer, Gerhard ^c   Baumgartner, Gerhard ^c   Wenzl, Etienne ^a   Hamilton, Gerhard ^a,c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF SALZBURG   (Austria)

^c LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

doxorubicin; drug carrier chemosensitivity; Ewing's sarcoma; MIC2; protein conjugate

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; GLYCOPROTEIN; TUMOR ANTIGEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG PROTEIN BINDING; DRUG TRANSPORT; EWING SARCOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; NEUROECTODERM; PRIORITY JOURNAL;

EID: 0029834964     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.9.3.527     Document Type: Article

References (18)

1. Harms D: New entities, concepts, and questions in childhood tumor pathology. Gen Diagn Pathol 141: 1-14, 1995.
2. Hamilton G, Fellinger EJ, Schratter I and A Fritsch: Characterization of a human endocrine tissue and tumor-associated Ewing's sarcoma antigen. Cancer Res 48: 6127-6131, 1988.
3. Ambros IM, Ambros PF, Strehl S, Kovar H, Gadner H and Salzer-Kuntschik M: MIC2 is a specific marker for Ewing's sarcoma and peripheral neuroectodermal tumors. Cancer 67: 1886-1893, 1991.
4. Kovar H, Dworzak M, Strehl S, Schnell E, Ambros IM, Ambros PF and H Gadner: Overexpression of the pseudoautosomal gene MIC2 in Ewing's sarcoma and peripheral neuroectodermal tumor. Oncogene 5: 1067-1070, 1990.
5. Felliger EJ, Garin-Chesa P, Su SL, DeAngelis P, Lane JM and Rettig WJ: Bichemical and genetic characterization of the HBA-71 Ewing's sarcoma cell surface antigen. Cancer Res 51: 336-340, 1991.
6. Darling SM, Banting GS, Pym B, Wolfe J and Goodfellow PN: Cloning an expressed gene shared by the human sex chromosomes. Proc Natl Acad Sci USA 83: 139-149, 1986.
7. + thymocytes. J Immunol 154: 26-32, 1995.
8. Hamilton G, Mallinger R, Hofbauer S and Havel M: The monoclonal HBA-71 antibody modulates proliferation of thymocytes and Ewing's sarcoma cells by interfering with the action of insulin-like growth factor I. Thymus 18: 33-41, 1991.
9. Kushner BH, Meyers PA, Gerald WL, et al: Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. J Clin Oncol 13: 2796-2804, 1995.
10. Triche TJ: Multiple-drug resistance in Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Am J Clin Pathol 102: 1-2, 1994.
11. Hofbauer S, Hamilton G, Theyer G, Wollmann K and Gabor F: Insulin-like growth factor I-dependent growth and in vitro chemosensitivity of Ewing's sarcoma and peripheral neuroectodermal tumor cell lines. Eur J Cancer 29: 241-245, 1993.
12. Gabor F, Wollmann K, Theyer G, Haberl I and Hamilton G: In vitro antiproliferative effects of albumin-doxorubicin conjugates against Ewing's sarcoma and peripheral neuroectodermal tumor cells. Anticancer Res 14: 1943-1950, 1994.
13. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
14. Way M, Pope B, Hawkins M and Weeds AG: Identification of a region in segment I of gelsolin critical for actin binding. EMBO J 9: 4103-4109, 1990.
15. Gelin C, Aubrit F, Phalipon A, Raynal B, Cole S, Kaczorek M and Bernard A: The E2 antigen, a 32 kd glycoprotein involved in T-cell adhesion processes, is the MIC2 gene product. EMBO J 8: 3253-3259, 1989.
16. Hijazi YM, Axiotis CA, Navarro S, Steinberg SM, Horowitz ME and Tsokos M: Immunohistochemical detection of P-glycoprotein in Ewing's sarcoma and peripheral primitive neuroectodermal tumors before and after chemotherapy. Am J Clin Pathol 102: 61-67, 1994.
17. Hurwitz E, Levy R, Maron R, Wilchek M, Arnon R and Sela M: The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities. Cancer Res 35: 1175-1181, 1975.
18. Dworzak MN, Fritsch G, Buchinger P, Fleischer C, Printz D, Zellner A, Schollhammer A, Steiner G, Ambros PF and Gadner H: Flow cytometric assessment of human MIC2 expression in bone marrow, thymus, and peripheral blood. Blood 83: 415-425, 1994.